Brain Cholesterol, Statins and Alzheimer’s Disease
The DOI matches its Crossref record.
Abstract
Growing evidence suggests that cellular cholesterol homeostasis is causally involved in different steps leading to pathological events in the brain of Alzheimer’s Disease (AD) patients. It was previously demonstrated that the processing of the amyloid beta-peptide precursor protein (APP) is modulated by pronounced alterations in cellular cholesterol levels using statins or cholesterol extracting agents. However, a cholesterol-rich diet was found to enhance amyloid beta-peptide (Aβ) burden in the brain of transgenic mice without clearly affecting total brain cholesterol levels. Recent retrospective epidemiological studies have reported that the use of statins potentially suppresses the development of AD. Although some HMG-CoA reductase inhibitors seem to influence the central cholesterol pool in vivo , the above epidemiological findings are probably not linked to statin-induced changes in brain membrane cholesterol levels per se since not all statins active in preventing AD enter the central nervous system (CNS). Recently, we reported that different statins, regardless of their brain availability, induce alterations in cellular cholesterol distribution in the brain. Such pleiotropic, cholesterol-synthesis independent statin effects might be indirect and are possibly mediated at the blood-brain barrier (BBB) via nitric oxide (NO) or apolipoprotein E (ApoE). Abbreviations Aβ:amyloid beta-peptide AD:Alzheimer’s disease ApoE:apolipoprotein E APP 3 :amyloid beta-peptide precursor protein BBB:blood-brain barrier CHD:coronary heart disease CHOD-PAP-cholesteroloxidase-peroxidase-aminophenazon-method:phenol-method CNS:central nervous system CSF:cerebrospinal fluid DHE:dehydroergosterol ER :endoplasmatic reticulum HMG-CoA:hydroxymethylglutaryl-coenzyme A MβCD:methyl-beta-cyclodextrin NO:nitric oxide NOs:nitric oxide synthase PUFA:polyunsaturated fatty acid SMC:smooth muscle cell SPM:synaptosomal plasma membrane SUV:small unilammelar vesicle TNBS:trinitrobenzensulfonic acid
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
Brain Cholesterol: Long Secret Life Behind a Barrier
Björkhem, I., & Meaney, S. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000120374.59826.1b · Cited by 1,044
Statin Safety: An Overview and Assessment of the Data—2005
Bays, H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.006 · Cited by 264
Ayurvedic medicinal plants for Alzheimer’s disease: A review
Rao, R. V., Descamps, O., John, V., & Bredesen, D. E. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt125 · Cited by 213
Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis
Wood, W. G., Li, L., Müller, W. E., & Eckert, G. P. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12637 · Cited by 194
“ApoE-knockout mice have peripheral atherosclerotic lesions and show highly elevated serum and liver cholesterol values, but brain cholesterol levels of these animals do not differ compared with agematched wild-type mice (Kirsch et al. 2003a).”
Self-citation
Metadata
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 2003-10
- Volume
- 36
- Pages
- 113-119
- ISSN
- 0176-3679 (ISSN-L)
- 0936-9528
- 1439-0795
- OpenAlex
- W2411824546
- Cited by
- 63
- References
- 0
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brain Cholesterol, Statins and Alzheimer’s Disease. https://app.cochat.ai/papers/10.1055/s-2003-43058
- The paper
- Brain Cholesterol, Statins and Alzheimer’s Disease. (2003). Pharmacopsychiatry. https://doi.org/10.1055/s-2003-43058
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.